ArticleDiseases (Basel, Switzerland)2025
Prognostic Role of TSH Within Euthyroid T2DM Patients with Retinopathy: A 3-Year Cohort Study.
Article in Diseases (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesWe aimed to determine how baseline TSH levels relate to clinical outcomes over a three-year follow-up in euthyroid patients with T2DR.
methodsThis single-center retrospective cohort study included 363 euthyroid T2DR patients who were followed for three years after baseline TSH measurement. Patients were stratified into tertiles based on TSH values belonging to the standard clinical limits (0.35-4.50 mIU/L). Binary and multivariate logistic regression analyses, along with non-linear modeling, were used to evaluate the prognostic impact of TSH and its interaction with age on mortality. The study adhered to the STROBE guidelines.
resultsIn the first year of follow-up, Group 1 (TSH 0.35-1.24 mIU/L) had significantly higher rates of mortality and combined outcomes compared to Group 2 (TSH 1.24-1.94 mIU/L;
conclusionsTSH values showed a non-linear association with outcomes in euthyroid T2DR patients. Group 2 was linked to the lowest risk. Given the significantly higher mortality and combined complications identified within Group 1, closer monitoring and individualized follow-up strategies may be warranted for these patients. Additionally, TSH's impact on long-term mortality increased with age, supporting its use alongside age for risk stratification in T2DR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.